GNCA - Genocea Biosciences Inc
Region: US
Website: www.genocea.com
Employees: 72
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.